Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Global Macro Funds Have Barely Cut Stock Exposure After the S&P 500’s Worst Week Since 2025, as Goldman Flags Up to $45 Billion of Systematic Selling

by Team Lumida
November 10, 2026
in Equities
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The positioning flush is not finished. Global macro hedge funds barely reduced their equity exposure as the S&P 500 posted its worst week since 2025, according to Goldman Sachs prime brokerage data cited by Bloomberg, even as retail investors and single-stock hedge funds headed for the exits.
  • Selling was concentrated in single names. Individual stocks saw the largest net selling in four months last week, while index and ETF macro products were net bought, Goldman’s data showed.
  • Systematic funds could add pressure. Goldman-tracked systematic signals are negative across about 60% of global equity markets, implying roughly $28 billion of potential selling in S&P 500 futures over the coming week and $45 billion over the next month.
  • Options positioning points to bigger swings. SpotGamma said negative gamma zones stretch across 7,000 to 7,550 on the S&P 500, which rose 2.4% Monday to close at 7,549.94; the bottom of that zone sits about 7.3% below Monday’s close by our calculation.

What Happened?

Last week’s US stock rout may have flushed out some of the market’s concentration excess but didn’t eliminate it, Bloomberg reported. “The good news is that positioning has come down to average levels from all-time highs,” said John Marshall, a partner at Carrick Lane. “The bad news is we haven’t come down so much that you can buy equities on positioning indicators alone.” Marshall noted that spreads on S&P 500 futures were stable last week and that macro investors have responded more to oil and rates than to AI news. On Tuesday, the S&P 500 fell 0.3% and the Nasdaq 100 slipped 0.1% after faster-than-estimated inflation sparked a bond rout on bets the Fed will keep lifting rates.

Why It Matters?

If macro funds, which have so far held on, start trimming as rates rise, the next leg of de-risking could hit index products rather than single stocks, which is where the selling was concentrated last week. Technical gauges also argue against calling a bottom: BTIG’s Jonathan Krinsky noted that 62% of S&P 500 companies still trade above their 200-day moving average, versus under 30% at typical sustainable lows, and put/call demand gauges remain well below the March and July bottoms. The Philadelphia Semiconductor Index closed below its 200-day moving average for the first time since May 2025, and historically its 50-day returns after such breakdowns have been negative on average. “Until those positions clear, the data suggests larger price swings in either direction remain likely,” SpotGamma analysts wrote.

What’s Next?

A dense run of catalysts follows Tuesday’s CPI report: Nvidia earnings on Nov. 17, the Anthropic IPO pricing and VIX options expiration on Nov. 18, and monthly equity options expiration on Nov. 20. Watch whether systematic selling in S&P 500 futures materializes near Goldman’s $28 billion one-week estimate, and whether the index can hold the 7,000 level at the low end of SpotGamma’s negative-gamma zone.

Affected Tickers and Coins: SPY, QQQ, SOXX, NVDA

Source: Bloomberg

Previous Post

Fox Kicks Off an About $8 Billion High-Grade Bond Sale in Up to Seven Tranches to Repay the $8.4 Billion Bridge Loan Behind Its Roku Deal

Next Post

SEC and CFTC Plan to Press Ahead With Crypto Rules Under Existing Authority Before Democrats Take Congress, After the CLARITY Act Failed

Recommended For You

Wall Street Pay Set to Rise Nearly 4% This Year, With Equities Traders’ Bonuses Up 30% or More as Volatility and IPOs Lift Bank Profits

by Team Lumida
8 seconds ago

Wall Street pay is on track to rise nearly 4% this year, with equities traders’ bonuses seen up 30% or more as volatility and IPOs boosted bank profits.

Read more

Rivian CEO Calls 2027 an ‘Inflection Year’ on R2 and Point-to-Point Autonomy, With the Stock Down More Than 80% Since Its IPO

by Team Lumida
5 minutes ago

Five years after its $78 IPO, Rivian’s CEO says the R2 SUV and autonomy make 2027 an ‘inflection year,’ even as Wall Street worries over cash burn.

Read more

Nvidia Slides a Second Straight Day as House China Panel Chair Moolenaar Demands Answers on Chip Sales, Lobbying and Leaked Information

by Team Lumida
5 minutes ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

Nvidia fell about 4% more Tuesday as Rep. Moolenaar pressed for answers on whether China got chip preference or privileged information via Huang’s affair.

Read more

Exxon Signs a Preliminary Deal to Explore Drilling in Venezuela, Nearly Two Decades After Its Exit and Months After Its CEO Called the Country ‘Uninvestable’

by Team Lumida
8 hours ago

Exxon signed a memorandum of understanding with Venezuela and PDVSA to evaluate drilling but says any investment needs stable policies and competitive returns.

Read more

Hims & Hers Swings to a Surprise $33 Million Loss as Gross Margin Falls to 57% From 74%, and Guides Q4 Revenue Well Below Estimates

by Team Lumida
8 hours ago

Hims & Hers posted a surprise loss as costs surged, narrowed its full-year sales outlook and guided Q4 revenue below estimates.

Read more

Take-Two’s Revenue Falls to $1.5 Billion and Misses Estimates, but It Raises Its Full-Year Outlook as CEO Zelnick Says ‘GTA VI’ Pre-Orders Are at Unprecedented Levels

by Team Lumida
8 hours ago

Take-Two’s revenue fell short as it narrowed its loss and raised its full-year revenue outlook, with GTA VI pre-orders at record levels ahead of Nov. 19.

Read more

Trump Says Jensen Huang Told Him He Had ‘No Idea’ His Affair Partner Was a Spy, as a Shareholder Class Action Hits Nvidia

by Team Lumida
8 hours ago
Nvidia Defies US Controls: $12 Billion AI Chip Sales in China

Trump said Huang denied knowing his affair partner was a Chinese spy and that the FBI is looking into it, as a class-action suit was filed against Nvidia.

Read more

Skydance Maps Out $6 Billion in Cost Cuts From Merging Paramount and Warner Bros. Discovery, and Warns of a $200 Million Box-Office Hit in Q4

by Team Lumida
8 hours ago
RedBird Puts $4 Billion More Into the $110 Billion Paramount-Warner Deal, Taking Its Stake to $6 Billion

Skydance detailed how it will cut $6 billion over three years, from back-office jobs to streaming, and flagged a $200 million fourth-quarter headwind.

Read more

Trade Desk Jumps as Much as 19% After Crushing Estimates With $736 Million in Revenue and Guiding Q4 to at Least $755 Million, as Sanmina Soars 20%

by Team Lumida
8 hours ago

Trade Desk beat on earnings and revenue and guided Q4 sales far above estimates, leading after-hours movers alongside Sanmina and Plug Power.

Read more

Surgery Partners Rejects a $28-a-Share Bid and Takes HealthSpan’s Sweetened $25 Offer, Valuing the Chain at About $6 Billion

by Team Lumida
1 day ago
Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds

Surgery Partners rose 12% premarket after HealthSpan raised its bid to $25 a share from $23.50; the board rejected a rival $28 offer as riskier.

Read more
Next Post

SEC and CFTC Plan to Press Ahead With Crypto Rules Under Existing Authority Before Democrats Take Congress, After the CLARITY Act Failed

Wall Street Pay Set to Rise Nearly 4% This Year, With Equities Traders’ Bonuses Up 30% or More as Volatility and IPOs Lift Bank Profits

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Amazon’s $100 Billion Bet: AI Over Retail

Amazon Unveils First Quantum Computing Chip, “Ocelot,” in Race to Solve Quantum Error Challenges

February 27, 2025
Microsoft’s AI Ambitions: A Costly Path Forward

Microsoft’s $80 Billion AI Infrastructure Bet: Largest Data Center Investment in Tech History

January 4, 2025
photo of gray and blue Transat airplane

War Sends Long-Haul Airfares Soaring 560% — And Relief Is Months Away

March 26, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018